CrushSCI.com
Journal Selection & Manuscript Polishing Services
LUNG CANCER journal cover Medicine
Back to journal directory

Review Cycle Records

LUNG CANCER

Elsevier SCIE Non-OA
2026 Emerging Zone 22025 CAS Zone 22025 JCR Q1
89.3Average days
88.5Median days
54Fastest days
169Longest days
6552025 publications

Paper Review Records

All Paper Review Records

10 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

169 days

Subtyping limited stage small cell lung cancer (LS SCLC) reveals inflammatory subtypes with improved chemoradiotherapy outcomes

AuthorsRafael Oliveira; Tarje Halvorsen; Kristin Killingberg; Elisabeth Fritzke Emdal; Vibeke Grotnes Dale; Bjørn Henning Grønberg; Pål Sætrom

AffiliationsDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway; Department of Oncology, St. Olavs Hospital HF, Trondheim University Hospital, Trondheim, Norway; Department of Pathology, St. Olavs Hospital HF, Trondheim University Hospital, Trondheim, Norway; Department of Computer Science, Norwegian University of Science and Technology (NTNU), Trondheim, Norway; St. Olavs Hospital HF, Central Staff, Trondheim University Hospital, Trondheim, Norway

Source PDF DOI Publisher page
84 days

Artificial intelligence–based assessment of tumor bed stroma in non–small cell lung cancer after neoadjuvant therapy: Association with pathologic response and survival. A multicenter study

AuthorsFederica Pezzuto; Luca Vedovelli; Giuseppe Maggioni; Francesco Fortarezza; Andrea Ascione; Angelina Pernazza; Daniele Marinelli; Debora Brascia; Salvatore Piscuoglio; Mariano Lombardi; Lorenzo Spaggiari; Domenico Galetta; Giulia Pasello; Marco Schiavon; Marco Anile; Andrea Dell’Amore; Dario Gregori; Paolo Graziano; Paolo Visca; Paola Bossi; Giuseppe Marulli; Elena Guerini Rocco; Giulia d’Amati; Fiorella Calabrese

AffiliationsUniversity of Padova, Via 8 Febbraio 2, 35122 Padova, Italy; Padova University Hospital, Via Giustiniani 2, 35128 Padova, Italy; Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy; University Hospital “Umberto I”, Viale del Policlinico 155, 00161 Rome, Italy; Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Rozzano, Italy; IRCCS Humanitas Research Hospital, Via Alessandro Manzoni 56, 20089 Rozzano, Italy; Division of Pathology, IEO European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; IRCCS, Veneto Institute of Oncology IOV, Via Gattamelata 64, 35128 Padova, Italy; IRCCS, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy

Source PDF DOI Publisher page
107 days

Adjuvant immunotherapy in resectable non-small cell lung cancer with nodal downstaging

AuthorsMengzhen You; Yang Pan; Cien Sun; Li Fu; Jiajing Sun; Yalun Li; Enguo Chen; Jianfei Shen; Jian Zeng; Feng Li

AffiliationsDepartment of Pulmonary Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, PR China; Department of Pulmonary and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Disease, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, PR China; Department of Thoracic Surgery, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Taizhou, PR China; Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, PR China; Department of Thoracic Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, PR China; School of Medicine, Zhejiang University, Hangzhou, PR China; Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, PR China

Source PDF DOI Publisher page
101 days

Utility of artificial intelligence for identifying thoracic lymphadenopathy in lung cancer

AuthorsMuhiddin Dervis; Anushree Burade; Michael Lanuti; Ibiayi Dagogo-Jack; Subba R. Digumarthy

AffiliationsDepartment of Radiology, Massachusetts General Hospital, Harvard Medical School 55 Fruit Street, Boston, MA 02114, USA; Department of Surgery, Massachusetts General Hospital, Harvard Medical School 55 Fruit Street, Boston, MA 02114, USA; Massachusetts General Brigham Cancer Institute, Harvard Medical School 55 Fruit Street, Boston, MA 02114, USA

Source PDF DOI Publisher page
54 days

Environmental asbestos exposure and lung cancer burden compared with mesothelioma in rural Türkiye: A 33-Year population-based cohort study

AuthorsGuntulu Ak; Selma Metintas; Nico van Zandwijk; Muzaffer Metintas

AffiliationsDepartment of Chest Diseases, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Türkiye; Lung and Pleural Cancers Research and Clinical Center, Eskisehir Osmangazi University, Eskisehir, Türkiye; Department of Public Health, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Türkiye; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Senior Staff Specialist, Sydney Local Health District (SLHD), Sydney, Australia; Department of Chest Diseases, Acıbadem Eskişehir Hospital, Eskişehir, Türkiye

Source PDF DOI Publisher page
68 days

Adding immunotherapy to chemotherapy may improve survival after SCLC transformation in EGFR-mutant NSCLC: a multicenter real-world study

AuthorsNazan Demir; Cevat İlteriş Kıkılı; Fatih Kemik; Bahadır Köylü; Deniz Tural; Şahin Laçin; Şeyda Gündüz; Didem Tunalı; Nil Molinas Mandel; Fulden Yumuk; Mevlude Inanc; Ayse Nuransoy Cengiz; Başak Oyan Uluç; Seval Ay Ersoy; Nisanur Sarıyar Busery; Serdar Karakaya; Dilek Erdem; Orhun Akdoğan; Ozan Yazıcı; Elanur Kahraman; İrem Bilgetekin; Umut Demirci; Hasibe Bilge Gür; İlker Nihat Ökten; Gökhan Karakaya; Oğuzhan Yıldız; Melek Karakurt Eryılmaz; Kübra Canaslan; Mustafa Seyyar; Muhammet Ali Kaplan; Erdem Çubukçu; Gül Akın; Mustafa Ersoy; Ahmet Taner Sümbül; Hakan Özçelik; Dilruba İlayda Özel Bozdağ; Ebru Çiçek; Ülviye Oflas; Fatma Paksoy Turkoz; Duygu Bayır Garbioğlu; Fatih Selçukbiricik

AffiliationsKoç University Hospital, Department of Medical Oncology, Istanbul, Turkey; American Hospital, Department of Medical Oncology, Istanbul, Turkey; Erciyes University, Department of Medical Oncology, Kayseri, Turkey; Acıbadem University School of Medicine, Acıbadem Altunizade Hospital, Department of Medical Oncology, Istanbul, Turkey; Kartal Dr Lütfi Kırdar City Hospital, Department of Medical Oncology, Istanbul, Turkey; Ankara Atatürk Sanotorium Training and Research Hospital, Department of Medical Oncology, Ankara, Turkey; Istinye University, Department of Medical Oncology, Istanbul, Turkey; Gazi University Faculty of Medicine Hospital, Department of Medical Oncology, Turkey; Karadeniz Technical University Faculty of Medicine, Department of Medical Oncology, Trabzon, Turkey; Memorial Ankara Hospital, Department of Medical Oncology, Ankara, Turkey; Sakarya Training and Research Hospital, Department of Medical Oncology, Sakarya, Turkey; Göztepe Prof. Dr. Süleyman Yalçın City Hospital , Department of Medical Oncology, Istanbul, Turkey; Özel ASV Yasam Hospital, Department of Medical Oncology, Antalya, Turkey; Necmettin Erbakan University School of Medicine, Department of Medical Oncology, Konya, Turkey; Dokuz Eylül University, Department of Medical Oncology, İzmir, Turkey; Gaziantep City Hospital, Department of Medical Oncology, Gaziantep, Turkey; Dicle University, Department of Medical Oncology, Diyarbakır, Turkey; Uludağ University Hospital, Department of Medical Oncology, Bursa, Turkey; Kütahya Health Sciences University, Department of Medical Oncology, Kütahya, Turkey; Medical Park Seyhan Hospital, Department of Medical Oncology, Adana, Turkey; Medipol University Hospital, Department of Medical Oncology, Istanbul, Turkey; Gülhane Training and Research Hospital, Department of Medical Oncology, Ankara, Turkey; Istanbul University Cerrahpaşa Faculty of Medicine, Department of Medical Oncology, Istanbul, Turkey; Düzce Ataturk State Hospital, Department of Medical Oncology, Düzce, Turkey; Bahcesehir University Faculty of Medicine, Department of Medical Oncology, Istanbul, Turkey; Osmangazi University Faculty of Medicine, Department of Medical Oncology, Eskişehir, Turkey

Source PDF DOI Publisher page
93 days

First-line pyrotinib plus apatinib in advanced non-small cell lung cancer harboring HER2 mutations or amplification: a phase II trial

AuthorsYaning Yang; Wenxin Jiang; Guangjian Yang; Weihua Li; Junling Li; Xuezhi Hao; Puyuan Xing; Siyu Lei; Fang Wei; Linyan Tian; Haiyan Xu; Yan Wang

AffiliationsDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; Centre de Recherche des Cordeliers, Équipe Labellisée par la Ligue Contre le Cancer, INSERM U1138, Université Paris Cité, Sorbonne Université, Paris 75006, France; Metabolomics and Cell Biology Platforms, Gustave Roussy Institut, Villejuif 94805, France; Department of Respiratory Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China; Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University & Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China; Department of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Chaoyang District, Beijing 100021, China

Source PDF DOI Publisher page
56 days

A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAFV600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study

AuthorsHuaqiang Zhou; Qing Zhou; Qisen Guo; Wei Guo; Gongyan Chen; Zhe Liu; Yun Fan; Yan Li; Yuh-Min Chen; Kenza Bouras; Laurence Del Frari; Angela Guo; Isabelle Klauck; Benoit Sansas; Li Zhang

AffiliationsDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong Province, China; Shandong Cancer Hospital, Huaiyin District, Jinan, Shandong Province, China; Shanxi Cancer Hospital, China; Harbin Medical University Cancer Hospital, Heilongjiang, China; Beijing Chest Hospital, Capital Medical University, China; Zhejiang Cancer Hospital, Zhejiang Cancer Center, Hangzhou, China; Chongqing Cancer Hospital, 181, Hanyu Road, Shapingba District, Chongqing, China; Clinical Research Center and Chest Department, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan; Pierre Fabre Laboratories, France; Pierre Fabre Laboratories, China

Source PDF DOI Publisher page
66 days

Macroscopic on-site evaluation for stratifying the incremental diagnostic benefit of additional sampling during endobronchial ultrasound-guided transbronchial needle aspiration

AuthorsTatsuya Imabayashi; Hiroyuki Hashimoto; Yuki Takahashi; Ikuyo Shionoya; Shun Futamura; Sayaka Uda; Tatsuya Yuba; Chieko Takumi; Shinsaku Tokuda

AffiliationsDepartment of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, 15-749, Honmachi, Higashiyama-ku, Kyoto 605-0981, Japan; Department of Infection Control, Japanese Red Cross Kyoto Daiichi Hospital, 15-749, Honmachi, Higashiyama-ku, Kyoto 605-0981, Japan; Department of Clinical Oncology, Japanese Red Cross Kyoto Daiichi Hospital, 15-749, Honmachi, Higashiyama-ku, Kyoto 605-0981, Japan

Source PDF DOI Publisher page
95 days

Genomic Profiling, Risk Stratification, and Post-Transformation Treatment Outcomes in Patients with Transformed Small-Cell Lung Cancer: A Multicenter Analysis

AuthorsRuolin Gao; ZhenXiang Li; Jie Huang; Jun Zhao; Yan Wang; Qinxiang Guo; Guangchuan Deng; Hua Bai; Xu Yang; Jianchun Duan; Zhijie Wang; Yuyan Wang; Jingjing Wang; Jiachen Xu; Rui Wan; Boyang Sun; Kailun Fei; Zixiao Ma; Jia Zhong; Jie Wang

AffiliationsState Key Laboratory of Molecular Oncology, Beijing Key Laboratory, CAMS Key Laboratory of Translational Research on Lung Cancer, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan City, 250117, China; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China; Department of Respiratory Medicine, Shanxi Province Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, TaiYuan, ShanXi 030013, China; Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Tianwen Avenue No. 288, Nan’an District, Chongqing 400010, China

Source PDF DOI Publisher page

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review96.4 days

Median77 days

Contact CrushSCI

Contact CrushSCI

Leave your contact details so we can discuss your manuscript, editing needs, and submission plan.

Selected service: Paper Editing Service

Or leave your contact details

WhatsApp, Telegram, WeChat, and email are all optional, but at least one is required. Once received, we will contact you as soon as possible.